Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.65 |
| ▸ | VEGFA | P15692 | 6/20 | 0.65 |
| ▸ | FLT1 | P17948 | 6/20 | 0.65 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.65 |
| ▸ | TET3 | O43151 | 1/20 | 0.59 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.59 |
| ▸ | ASPH | Q12797 | 1/20 | 0.59 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.59 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.59 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.59 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.59 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920959 | 1.00 | EGLN1 (0.65) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL1921260 | 0.89 | EGLN1 (0.65) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3480520 | 0.88 | EGLN1 (0.63) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3484350 | 0.88 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL1921669 | 0.87 | EGLN1 (0.68) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL29772956 | 0.87 | EGLN1 (0.68) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL1921289 | 0.86 | EGLN1 (0.61) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3485494 | 0.85 | PIK3CD (0.47) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3485418 | 0.83 | EGLN1 (0.63) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3047464 | 0.82 | EGLN1 (0.62) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |